Summary of Xiansheng Pharmaceutical Conference Call Company Overview - **Company**: Xiansheng Pharmaceutical - **Industry**: Pharmaceutical, focusing on oncology and neurology Key Points Oncology Pipeline Highlights - **Core Products**: - Enze Shou (苏维西西达单抗) has been approved and included in the medical insurance directory, showing clear overall survival (OS) benefits for platinum-resistant ovarian cancer [6] - Kexaila (曲拉西利) is a CDK46 inhibitor, conditionally approved in 2022, expected to enter the medical insurance directory by the end of 2024 [6] - Enlituz (EGFR monoclonal antibody) is also expected to enter the medical insurance directory by the end of 2024 [6] New Product Launches - **Dali Le Sheng**: A new insomnia drug with significant market potential, expected to enhance performance rapidly. It reaches plasma peak in 1-2 hours and has an 8-hour half-life, aligning with human sleep cycles [2][3][7] - **Future Innovations**: Multiple innovative drugs are expected to launch in the coming years, including: - Madunosawe (抗流感), anticipated approval in 2026 [11] - New RSV infection drug, currently in slower clinical progress [11] Research and Development Investments - **R&D Spending**: In the first half of 2025, R&D investment reached 1.03 billion yuan, accounting for approximately 29% of revenue [4] - **Funding**: Raised 1.5 billion HKD through share placement, with 90% allocated for R&D [4] - **BD Collaborations**: Significant partnerships with companies like AbbVie, indicating international recognition of innovation capabilities [5] Market Potential and Competitive Landscape - **Insomnia Market**: The insomnia prevalence in China is 29.2%, with Dali Le Sheng addressing unmet needs in sleep onset and maintenance without next-day drowsiness [7][10] - **Safety Profile**: Dali Le Sheng is classified as a non-controlled substance, indicating a high safety profile and no addiction potential, allowing for broader market access [10] Financial Projections - **Short-term Growth**: Existing products entering the medical insurance directory and new launches like Dali Le Sheng are expected to drive revenue and profit growth [8][14] - **Long-term Outlook**: Continuous R&D investment and a robust pipeline suggest sustained growth momentum, with a target price of 20.16 HKD and a total market value of 48 billion RMB, indicating over 60% upside potential from current prices [4][8] Risks and Challenges - **Market Risks**: Potential risks in the autoimmune sector, particularly with the consistency evaluation of existing products, but new products like Jack One inhibitors are expected to mitigate these risks [15][16] Summary of Current Pipeline Performance - **Core Products**: The existing pipeline is performing well, with significant market share for key products like Xianbixin injection [15] - **Growth Opportunities**: New indications for existing drugs, such as Shisuan Jianjia for post-stroke cognitive impairment, are being explored for additional growth [16]

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of InventisBio Co., Limited 益方生物科技（上海）股份有限公司 (the "Company") (A joint stock ...

Core Viewpoint - Yifan Pharmaceutical (002019) is experiencing significant growth in its core innovative drug, Yilishu, with a notable increase in both domestic and international shipments, indicating a strong market presence and potential for future performance enhancement [1][2][5] Group 1: Product Performance - Yilishu's cumulative shipment volume in domestic and international markets has exceeded 500,000 units, with a year-on-year growth rate of over 80% [1] - The product has achieved a terminal price of $4,600 per unit in the U.S. market, with shipments surpassing 46,000 units, showcasing the effectiveness of the company's international expansion strategy [1] - Another innovative drug, Yinikang, has also shown impressive performance, with a cumulative shipment volume growth exceeding 200% year-on-year [1][3] Group 2: Regulatory and Clinical Advancements - Yilishu has received significant endorsements from authoritative guidelines, being included as a top recommendation in multiple international cancer treatment guidelines [2] - The drug's clinical study, Guard-02, has been selected for presentation at the prestigious ESMO annual meeting, further solidifying its position in the oncology support treatment market [2] Group 3: Research and Development Progress - The company has multiple innovative products in its pipeline, including the approval of N-3C01 injection for clinical trials targeting advanced solid tumors and non-muscle invasive bladder cancer [3] - The company is also advancing its clinical trials for various other products, including a compound for treating advanced recurrent platinum-resistant ovarian cancer [3] Group 4: Globalization and Business Development - In 2025, the global business development (BD) center was established to enhance the company's capabilities in product transactions, cross-border negotiations, and market expansion [4] - The BD center aims to create a unique business model that integrates both inbound and outbound strategies, focusing on localizing multinational products and promoting domestic innovative drugs globally [4] Group 5: Industry Outlook - The innovative drug sector is viewed as a promising area for growth within the pharmaceutical industry, supported by favorable policies and a global commercialization trend [5] - As Yifan Pharmaceutical's innovative pipeline matures, the company's growth potential and long-term investment value are expected to become more pronounced, offering investors both certainty and growth opportunities [5]

Core Insights - The Chinese pharmaceutical industry is experiencing a significant breakthrough in innovative drug development, marking a decade of progress since 2015, which was recognized as the "Year of Chinese Innovative Drugs" [1][5] - Chronic Kidney Disease (CKD) is emerging as a global public health challenge, with approximately 788 million adults affected worldwide in 2023, highlighting the urgent need for new treatment options [2] - The CAR-T therapy shows promise in addressing kidney disease by targeting pathogenic cells, although initial trials faced challenges [3] Industry Developments - The Chinese government has implemented supportive policies for innovative drug development, including a comprehensive support system that enhances the entire drug development chain [3][4] - Since the "14th Five-Year Plan," over 110 innovative drugs have been approved in China, with the market size reaching 100 billion yuan, and the country now ranks second globally in new drug research and development [5][6] - The approval of 265 innovative drugs since 2018, with a significant increase in approvals in 2025, reflects the growing optimism in the industry regarding the drug development cycle [6] Market Opportunities - By 2030, many major multinational pharmaceutical companies will face patent expirations, creating opportunities for Chinese innovative drugs in areas like tumor immunotherapy and other therapeutic fields [6] - The overseas licensing of Chinese innovative drugs is projected to exceed 100 billion USD by 2025, indicating a shift from simple licensing to collaborative development models [7] - The transformation of Chinese pharmaceutical companies from "sellers" to "partners" in global markets signifies a strategic evolution towards original innovation [7] Future Challenges - The industry must transition from "fast following" to "best in class" and ultimately to "first in class" innovations, necessitating collaboration among research, policy, and capital [8] - Continued patience, courage, and wisdom are required to navigate the complexities of the evolving pharmaceutical landscape in China [8]

Core Viewpoint - Junshengtai Pharmaceutical is leveraging innovative molecules derived from natural products to address metabolic diseases, emphasizing a patient-centered approach to meet unmet clinical needs [2][3]. Group 1: Company Overview - Junshengtai Pharmaceutical was founded by Liu Liping in 2011, focusing on the research and development of drugs for metabolic diseases [3]. - The company aims to explore the potential of natural products in drug development, moving away from traditional methods of producing generic drugs [3]. Group 2: Product Development - The company has developed a novel molecular entity, HTD1801, by combining berberine from traditional Chinese medicine and ursodeoxycholic acid, targeting multiple pathways for treating various metabolic diseases [2][4]. - HTD1801 has shown potential in activating AMPK, improving glucose uptake, and reducing chronic inflammation, which are critical for managing metabolic disorders [4]. Group 3: Clinical Trials and Applications - Junshengtai Pharmaceutical has initiated two Phase 3 clinical trials for HTD1801 in Chinese patients with Type 2 Diabetes Mellitus (T2DM), achieving primary and multiple secondary efficacy endpoints [5]. - The company plans to submit a new drug application for HTD1801 for T2DM treatment and has identified chronic kidney disease (CKD) as an additional indication [5][6]. Group 4: Future Prospects - HTD1801 is expected to expand its indications, with ongoing research into its effects on CKD and potential combination therapies with GLP-1 receptor agonists for obesity management [6]. - The company aims to position HTD1801 as a foundational treatment in the cardiovascular-kidney-metabolic (CKM) field, providing comprehensive health solutions for patients [6]. Group 5: Innovation and Challenges - Liu Liping likens the process of developing innovative drugs to climbing Mount Everest, highlighting the challenges faced in combining natural molecules into a new compound [7]. - The company emphasizes a focus on breakthrough innovations and overcoming obstacles in drug development, reflecting the broader trends in China's pharmaceutical industry [7].

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 87.6 CNY per share [2][10]. Core Insights - The report emphasizes the company's differentiated innovation capabilities, particularly through the integration of its research and development (R&D) systems, which is expected to enhance its competitive edge in the pharmaceutical market [8][9]. - The company has made significant strides in its product pipeline, particularly in the controlled narcotics sector, and is poised to become a leader in this field [26][27]. - The integration of Shanghai Chaoyang, focusing on targeted protein degradation, is expected to bolster the company's R&D capabilities and expand its product offerings [9][10]. Financial Summary - Total revenue projections for 2024A, 2025E, 2026E, and 2027E are 1,350 million, 1,376 million, 1,567 million, and 1,933 million CNY respectively, with year-on-year growth rates of 20.8%, 2.0%, 13.8%, and 23.4% [3]. - Net profit attributable to shareholders is forecasted to be 238 million, 277 million, 316 million, and 388 million CNY for the same years, reflecting growth rates of 5.1%, 16.2%, 14.0%, and 22.9% [3][10]. - The price-to-earnings (PE) ratios are projected to be 44, 38, 34, and 27 for the years 2024A to 2027E [3]. R&D and Product Pipeline - The company has established a robust pipeline in the controlled narcotics sector, with recent approvals for key products such as Buprenorphine and Butorphanol, which are expected to significantly contribute to revenue growth [26][28]. - The report highlights the potential of HP-001, a leading candidate in the targeted protein degradation space, which has shown promising clinical results [9][10]. - The integration of R&D efforts between Chengdu Yuandong and Shanghai Chaoyang is anticipated to create a dual-pathway for innovation, enhancing the company's overall R&D efficiency [9][10].

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 自願性公佈 聯康集團與溫醫大國家工程研究中心及 溫州市甌海區人民政府達成戰略合作 香港，二零二五年十二月三十日 — 聯康生物科技集團有限公司（「本公司」），連 同其附屬公司統稱（「本集團」）董事會（「董事會」）欣然宣佈，於近日在浙江省溫州 市，本集團與溫州醫科大學細胞生長因子藥物和蛋白製劑國家工程研究中心（「溫 醫 大 國 家 工 程 研 究 中 心 」）及 溫 州 市 甌 海 區 人 民 政 府 正 式 簽 署 三 方 戰 略 合 作 協 議 （「協議」），並就後續共建「聯康 — 溫醫大轉化醫學聯合創新實驗室（」「聯合實驗 室」）事宜進行探討。此次合作有助於強化本集團在皮膚 ...

Core Viewpoint - The company, Haishi Ke (002653.SZ), has received approval from the National Medical Products Administration for clinical trials of its new drug HSK44459, aimed at treating inflammatory bowel diseases, including ulcerative colitis and Crohn's disease [1] Group 1: Drug Development - HSK44459 is a novel small molecule drug developed independently by the company, possessing independent intellectual property rights [1] - The drug has shown clear targets, definite efficacy, and good safety in preclinical studies, indicating high development potential [1] - The clinical application of HSK44459 is expected to address the current shortage of effective treatments for inflammatory bowel diseases [1] Group 2: Clinical Trial Approval - The clinical trial application for HSK44459 was accepted in October 2025 and meets the requirements for drug registration as per the relevant regulations [1] - The approval allows the company to proceed with clinical trials, which is a significant step in the drug development process [1]

SK50042是公司自主研发的口服、强效、高选择性小分子抑制剂药物，拟用于呼吸系统疾病的治疗。临 床前研究表明，HSK50042在较低剂量下即可有效改善模型小鼠的肺部疾病病理症状，具有良好的药效 作用，同时也表现出了良好的耐受性和较大的安全窗，是一款极具开发潜力的药物。本次申请为 HSK50042片在呼吸系统疾病领域中又一新适应症的临床试验申请，有望为呼吸疾病患者提供一种高 效、安全的新型治疗选择。 HSK55879片是公司自主研发的具有独立知识产权的口服小分子激动剂药物，拟用于代谢系统疾病的治 疗。临床前研究数据表明，HSK55879在相关动物模型中表现出显著的药效活性，作用机制明确，且在 不同剂量下均显示出良好的耐受性，同时拥有较大的安全窗。综合现有结果，HSK55879具备明确的开 发价值和良好的转化前景，有望为临床患者提供一种高效、安全的新型治疗选择。 智通财经APP讯，海思科(002653.SZ)发布公告，公司子公司上海海思盛诺医药科技有限公司于近日收到 国家药品监督管理局下发的《受理通知书》，涉及产品："HSK50042"、"HSK55879"。 ...

Core Viewpoint - Aosaikang (002755) has entered into a licensing agreement with Hangzhou Anuo Biopharmaceutical Technology Co., Ltd. for the exclusive rights to develop, manufacture, and commercialize the innovative drug AN9025 in the designated region [1] Group 1: Licensing Agreement Details - Aosaikang's subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., will pay a one-time, non-refundable, and non-offsettable upfront payment of 35 million RMB to Anuo Biopharma within 10 working days after the agreement takes effect [1] - The total milestone payments for product development, registration, and market launch will not exceed 470 million RMB, with additional payments of up to 1.128 billion RMB tied to sales milestone events [1] Group 2: Product Information - AN9025 is a novel oral pan-RAS inhibitor that can simultaneously bind to activated RAS-GTP and molecular chaperone (Cyclophilin A), effectively inhibiting various types of KRAS, NRAS, and HRAS mutations [1] - The drug is intended for the treatment of RAS-mutant solid tumors and has completed Investigational New Drug (IND) applications in both China and the United States, receiving FDA approval for clinical trials [1] Group 3: Financial Implications - Aosaikang will pay a tiered royalty fee based on annual net sales once the product achieves commercial sales in the licensed region [1]